Study Comparing Blood Markers MPV, PLR, and NLR in Primary and Secondary Antiphospholipid Syndrome
Led by New Valley University · Updated on 2026-07-31
150
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Antiphospholipid syndrome APS is an autoimmune disorder characterized by blood clots and pregnancy complications, with varied clinical presentations. It can occur as a primary condition or secondary to other autoimmune diseases like systemic lupus erythematosus. This research evaluates blood markers linked to inflammation and immune response, including mean platelet volume MPV, platelet-to-lymphocyte ratio PLR, and neutrophil-to-lymphocyte ratio NLR, in primary versus secondary APS cases.
Participants undergo diagnostic tests such as complete blood counts to measure MPV, PLR, and NLR, along with assessments of antiphospholipid antibody profiles. These blood markers are studied for their potential to reflect inflammation and platelet activity related to APS. The study compares these markers between primary APS and secondary APS groups to understand differences in disease processes.
During the study, participants provide blood samples for analysis of these hematological markers. Researchers will evaluate baseline measurements of MPV, PLR, and NLR in both APS types. The study monitors these markers to explore their role in APS diagnosis and prognosis. Participation involves blood testing without active treatment, and the study duration covers from screening through baseline assessments.
CONDITIONS
Brief Title
Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Research Team
A
Asmaa Nady Hussein, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of APS based on updated Sydney classification criteria confirmed by clinical history of thrombosis and/or pregnancy morbidity
Persistent presence (�b�812 weeks) of antiphospholipid antibodies (aCL, anti-�b�822-glycoprotein I, and/or lupus anticoagulant)
You will not qualify if you...
Current infection or inflammatory condition unrelated to APS
Hematological malignancies or other blood disorders
Recent blood transfusion or platelet-altering medications other than APS treatments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Exploratory Study Evaluating Safety and Initial Effectiveness of YTS109 Cell Injection in Adults with Recurrent or Refractory Autoimmune Diseases
Study of YTS109 Cell Treatment for Adults Aged 18-65 with Relapsed or Refractory Autoimmune Diseases Including Lupus and Sjogrens Syndrome
Study of Anti-CD19 IL-10IL15 CAR-NK Cell Therapy for Adults with Refractory or Relapsed Autoimmune Diseases Including Lupus, Sclerosis, Myositis, Vasculitis, Sjogrens, and Antiphospholipid Syndrome
Study of BCMA-CD19 CAR-T Cell Therapy for Adults with Difficult-to-Treat Autoimmune Diseases
Study of Autoreactive B Lymphocytes in Autoimmune Diseases and Immune Deficiencies Observational Study
Evaluation of BCT301 CAR-iT Cell Therapy for Treatment-Resistant Autoimmune Diseases Using Chemically Induced Pluripotent Stem Cells
Studying Annexin A2 Levels on Monocytes in Adults with Primary Antiphospholipid Syndrome Using Flow Cytometry
Study of YTS109 Cell Therapy for Adults Aged 18-65 With Relapsed or Refractory Autoimmune Diseases Including Lupus, Sjogrens Syndrome, and Others
Study of Genetic Factors in Families Affected by Antiphospholipid Antibody Syndrome and Related Autoimmune Disorders
Study Comparing Blood Markers MPV, PLR, and NLR in Primary and Secondary Antiphospholipid Syndrome
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Diagnostic value of Platelet/lymphocyte Ratio (PLR) for predicting sentinel axillary lymph node positivity in early-stage breast cancer compared with ultrasonography.
Şevket Barış Morkavuk, Servet Kocaöz, Birol Korukluoğlu
Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness.
Artemio García-Escobar, Silvio Vera-Vera, Daniel Tébar-Márquez...